Mylan-Biocon ’s insulin biosimilar faces FDA hurdle

Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news